

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
15 September 2005 (15.09.2005)


PCT

(10) International Publication Number
WO 2005/084439 A1

- (51) International Patent Classification⁷: **A01N 43/00**,
A61K 31/33
- (21) International Application Number:
PCT/US2005/007238
- (22) International Filing Date: 2 March 2005 (02.03.2005)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
200460/549,418 2 March 2004 (02.03.2004) US
11/070,394 1 March 2005 (01.03.2005) US
- (63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:
US 60/549,418 (CON)
Filed on Not furnished
- (71) Applicant (for all designated States except US): **DOV
PHARMACEUTICAL, INC.** [US/US]; 433 Hackensack
Avenue, Hackensack, NJ 07601-6382 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **SKOLNICK,
Phil** [US/US]; 433 Hackensack Ave, Hackensack, NJ
07601-6382 (US).
- (74) Agents: **KING, Jeffrey, J.** et al.; Graybeal Jackson Haley
LLP, 155 - 108th Avenue N.E., Suite 350, Bellevue, WA
98004-5973 (US).
- (81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US (patent), UZ, VC, VN,
YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report

[Continued on next page]

(54) Title: 2-PYRIDINYL[7-(SUBSTITUTED-PYRIDIN-4-YL)PYRAZOLO[1,5-A]PYRIMIDIN-3-YL]METHANONES



(I)

(57) **Abstract:** The present invention provides novel 2-pyridinyl[7-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones with at least one substituent on the 4-pyridinyl ring having the chemical structure of formula (I): The invention further provides compositions and methods employing the novel 2-pyridinyl[7-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl]methanones of formula: (I) in to modulate GABA and GABA receptor physiology to elicit therapeutic responses in mammalian subjects to alleviate neurological or psychiatric disorders, including stroke, head trauma, epilepsy, pain, migraine, mood disorders, anxiety, post traumatic stress disorder, obsessive compulsive disorders, mania, bipolar disorders, schizophrenia, seizures, convulsions, tinnitus, neurodegenerative disorders including Alzheimer's disease, amyotrophic lateral sclerosis and Parkinson's disease, Huntington's chorea, depression, bipolar disorders, mania, trigeminal and other neuralgia, neuropathic pain, hypertension, cerebral ischemia, cardiac arrhythmia, myotonia, substance abuse, myoclonus, essential tremor, dyskinesia and other movement disorders, neonatal cerebral hemorrhage, and spasticity, as well as other psychiatric and neurological disorders mediated by GABA and/or GABA receptors.

WO 2005/084439 A1



— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.